{"organizations": [], "uuid": "38344a6e0051568aa8e70f2205e6053914ec7ae6", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-protalix-biotherapeutics-pegunigal/brief-protalix-biotherapeutics-pegunigalsidase-alfa-receives-fast-track-designation-from-fda-idUSASB0C37I", "country": "US", "domain_rank": 408, "title": "BRIEF-Protalix Biotherapeutics' Pegunigalsidase Alfa Receives Fast Track Designation From FDA", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-31T14:38:00.000+02:00", "replies_count": 0, "uuid": "38344a6e0051568aa8e70f2205e6053914ec7ae6"}, "author": "", "url": "https://www.reuters.com/article/brief-protalix-biotherapeutics-pegunigal/brief-protalix-biotherapeutics-pegunigalsidase-alfa-receives-fast-track-designation-from-fda-idUSASB0C37I", "ord_in_thread": 0, "title": "BRIEF-Protalix Biotherapeutics' Pegunigalsidase Alfa Receives Fast Track Designation From FDA", "locations": [], "entities": {"persons": [{"name": "pegunigalsidase alfa rec", "sentiment": "negative"}], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "brief-protalix biotherapeutics", "sentiment": "negative"}, {"name": "protalix biotherapeutics inc", "sentiment": "none"}, {"name": "fda reuters", "sentiment": "none"}, {"name": "alfa", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "January 31, 2018 / 12:39 PM / in 22 minutes BRIEF-Protalix Biotherapeutics' Pegunigalsidase Alfa Receives Fast Track Designation From FDA Reuters Staff 1 Min Read \nJan 31 (Reuters) - Protalix Biotherapeutics Inc: \n* PROTALIX BIOTHERAPEUTICSâ€™ PEGUNIGALSIDASE ALFA RECEIVES FAST TRACK DESIGNATION FROM THE U.S. FOOD AND DRUG ADMINISTRATION Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-01-31T14:38:00.000+02:00", "crawled": "2018-01-31T15:08:13.020+02:00", "highlightTitle": ""}